Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Lanthier M, Miller KL, Nardinelli C, et al.: An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987–2011. Health Aff (Millwood). 2013, 32 (8): 1433-1439. 10.1377/hlthaff.2012.0541.
2. Schwartz LM, Woloshin S: Communicating uncertainties about prescription drugs to the public a national randomized trial. Arch Intern Med. 2011, 171 (16): 1463-1468. 10.1001/archinternmed.2011.396.
3. Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC): Drug Utilisation Sub-Committee Outcome Statement 7–8. 2013, City; 2013 [cited Available from:
http://www.pbs.gov.au/info/reviews/diabetes#Stage3
, February
4. Sobrero A, Bruzzi P: Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol. 2009, 27 (35): 5868-5873. 10.1200/JCO.2009.22.4162.
5. Fojo T, Grady C: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009, 101 (15): 1044-1048. 10.1093/jnci/djp177.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献